RxDoctor Payments Data

Laura Landgraf, PA

Medical · Gurnee, ILNPI 1679779227

Payments from drug & device makers

$3,130in general payments, 2019–2025

Across 122 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$929
  • Novartis$678
  • AstraZeneca$212
  • Boehringer Ingelheim$184
  • Edwards Lifesciences$162
  • Boston Scientific$158
  • plus $806 from 14 others

What the payments were for

  • Food & beverage$3,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,130 in reported general payments places this provider in the 80th percentile of 449 medical providers in Illinois.

See all medical providers in Illinois

Medicare billing

Part B allowed, 2024
$34,772
Medicare patients
271
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$70,668
OzempicSemaglutide35$59,784
JardianceEmpagliflozin30$32,886
XareltoRivaroxaban23$29,721
EntrestoSacubitril/Valsartan27$26,328
Ezetimibe59$2,029
Clonidine13$1,285
Atorvastatin Calcium92$1,070
Metoprolol Succinate78$1,063
Carvedilol87$957
Spironolactone-HctzSpironolact/Hydrochlorothiazid12$734
Spironolactone84$722
Amlodipine Besylate107$668
Losartan Potassium46$607
Torsemide31$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$70,66872 claims
Novo NordiskOzempic$929$59,78435 claims
Boehringer IngelheimJardiance$184$32,88630 claims
Johnson & JohnsonXarelto$155$29,72123 claims
NovartisEntresto$678$26,32827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 449 medical providers in Illinois.

Other medical in Gurnee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →